


モンテルカストナトリウム顆粒 (米国薬局方原案記載条件)

Montelukast sodium oral granules (The draft for The United States Pharmacopoeia)


H150501C

(A) Dissolution: Standard solution
(4.4 µg/mL Montelukast)




	System suitability requirement	Result
Tailing factor (Montelukast)	≤ 1.5	1.08
Relative standard deviation of peak area (n=5) (Montelukast)	≤ 2.0%	0.12%

(B) Uniformity of dosage units: Standard solution
(0.020 mg/mL Montelukast)



	System suitability requirement	Result
Tailing factor (Montelukast)	≤ 1.5	1.09
Relative standard deviation of peak area (n=5) (Montelukast)	≤ 2.0%	0.15%



1. Montelukast

Column : YMC-Pack Ph (5 µm, 12 nm)
100 X 3.0 mmI.D.
Eluent : acetonitrile/water/TFA (500/500/2)
Flow rate : 0.9 mL/min
Temperature : 50°C
Detection : UV at 389 nm
Injection : A) 25 µL, B) 5 µL

(The draft for The United States Pharmacopoeia 40th; Dissolution, Uniformity of dosage units)

*All Standard solutions were prepared from Montelukast sodium salt hydrate supplied as a reagent for laboratory use.